Location:Home & Faculty & Faculty and Staff
Shen Jingkang
Education:
Positions:
Professor/Ph.D candidate supervisor, Principal Investigator
Academic title:
+86-021-0, +86-021-
Personal Website:
Postal Code:
Mailing Address:
555 Zuchongzhi Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, P.R.China.
Shen Jingkang graduated from School of Pharmacy at Shanghai Medical University in 1975 and received MS degree in Medicinal Chemistry from the same university in 1986. After studied in Japan for 4 years he obtained his Ph. D degree at Kyoto University in 1993. He joined Shanghai Institute of Materia Medica, CAS in 1994 and promoted as professor in Medicinal Chemistry in 1995. His current research interests include discovery of targeted anticancer drugs, and development new methods for drug discovery. EDUCATION 05/1975 School of Pharmacy, Shanghai Medical University, China 09/1986 School of Pharmacy, Shanghai Medical University, China for Ms degree 09/1993 School of Pharmacy, Tokyo University, Japan for Doctor of Pharmacy WORK EXPERIENCE: Assistant, School of Pharmacy, Shanghai Medical University, China : Lectuer, School of Pharmacy, Shanghai Medical University, China : Research and teaching Assistant, Niigata College of Pharmacy, Japan : Postdoctoral Researcher, Shanghai Institute of Materia Medica. 1995-present: Professor, Shanghai Institute of Materia Medica, CAS 1996: Visiting Professor, School of Pharmacy, University of North Carolina at Chapel Hill, USA
Research Directions
Discovery and development of molecular targeted anti-tumor drugs , including protein tyrosine kinase inhibitors, epigenetic-related protein modulators and monoclonal anti Studies on synthetic methods and compound library construction for d rug discovery.
Social Titles
Member of Editorial Advisory Board of ACS Medicinal Chemistry Letters Member of Editorial Advisory Board of Drugs of the Future Vice Direcotr, the Medicinal Chemistry committee of Chinese Pharmaceutical Association Vice Chairman,Shanghai Pharmaceutical Association
Awards & Honors
1998: Second Level Technology Advance Award of Shanghai City 1999: Third Level Technology Advance Award of Shanghai City
Achievements
1. Discovery and development of targeted anti-tumor drugs 1) Kinase inhibitor development (1) Discovery and development of selective cMet inhibitors(2) PI3K/mTOR inhibitors2）Epigenetics drug discovery Developing drugs targeted important epigenetic proteins 3) Research on Antibody Drug Conjugates Development of the platform of antibody drug conjugates, including its preparation and analysisThe application and discovery of highly potent payloads in ADC&2. Drug discovery methodology 1) Chemoinformatics We developed new methods and technologies in drug discovery based on the analysis of large scale data and computational modeling. 2) Synthesis of heterocyclic compound libraries Synthesis of heterocyclic compound libraries containing privileged structure based on multicomponent reaction 3. Others Carbohydrate chemistry and carbohydrate based drug discovery.
Grants & Research Projects
1. The National Basic Research Program of China( “973” Program) (1 sub-project) 2. The National High Technology Research and Development Program of China (863 Program) (1 sub-project) 3. International cooperation project of Ministry of science and technology (1 project) 4. Major drug discovery of national science and technology special topic(8 projects) 5. The natural science foundation of China(NSFC) ( 7 General Projects, 3 Projects for Young Scholars, 1 Key Project) 6. The programs of the Chinese Academy of Sciences (5 projects)
Pubilcations
(-)1. Gu X.; Chen L.; Wang X.; Liu X.; You Q.; Xi W.; Gao L.; Chen G.*; Chen Y.-L.*; Xiong B.*; Shen J.*, Direct Glycosylation of Bioactive Small Molecules with Glycosyl Iodide and Strained Olefin as Acid Scavenger. The Journal of Organic Chemistry, ), . &2. Ma Y.; Liang J.; Zhao D.; Chen Y.-L.*; Shen J.*; Xiong B*. Condensed Fukui function predicts innate C-H radical functionalization sites on multi-nitrogen containing fused arenes. RSC Advances 4 , -17264. &3. Tao Meng, Wei Wang, Zhixiang Zhang, Lanping Ma*, Yongliang Zhang, Zehong Miao*, Jingkang Shen* , Synthesis and biological evaluation of 6H-pyrido[20,10:2,3]imidazo[4,5-c]isoquinolin-5(6H)-ones as antimitotic agents and inhibitors of tubulin polymerization, Bioorg Med Chem, 22 ,5 &4. Shanshan Li#, Bing Xiong#, Yuan Xu, Tao Lu, Xiaomin Luo, Cheng Luo, Jingkang Shen, Kaixian Chen, Mingyue Zheng, and Hualiang Jiang ,Mechanism of the All-α to All-β Conformational Transition of RfaH-CTD: Molecular Dynamics Simulation and Markov State Model J. Chem. Theory Comput., ), pp . &5. Ren J, Li J, Wang Y, Chen W, Shen A, Liu H, Chen D, Cao D, Li Y, Zhang N, Xu Y, Geng M, He J, Xiong B*, Shen J*. Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.Bioorg Med Chem Lett. 2014 Jun 1;24(11): . &6. Jiang R.-w.; Du X.-g.; Zhang X.; Wang X.; Hu D.-y.; Meng T.; Chen Y.-L.; Geng M.-y.*; Shen J.-k.*, Synthesis and bioassay of beta-(1,4)-D-mannans as potential agents against Alzheimer's disease. Acta Pharmacologica Sinica, , ), . &7. Shen J.; Zhang L.; Song W.L.; Meng, T.; Wang, X.; Chen, L.; Feng, L.Y; Xu, Y.C.; Shen, J.K.*; Design, Synthesis and Biological Evaluation of Bivalent Ligands Against A1-D1 Receptor Heteromers. Acta Pharmacologica Sinica. 1-452. &8. Ahmad Mirza, David L. Burk, Bing Xiong, Hiroaki Iwaki, Yoshie Hasegawa, Stephan Grosse,Peter C. K. Lau*, Albert M. Berghuis. Structural Analysis of a Novel Cyclohexylamine Oxidase from Brevibacterium oxydans IH-35A, PLoS ONE 8(3): e60072. &9. Zhao L, Cao D, Chen T, Wang Y, Miao ZH, Xu Y, Chen W, Wang X, Li Y, Du Z,Xiong B*, Li J, Xu C, Zhang N, He J, Shen J*. Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain. J Med Chem. ), pp . &10. Zheng M, Li Y, Xiong B*, Jiang H, Shen J*. Water PMF for Predicting the Properties of Water Molecules in Protein Binding Site. J Comput Chem. 2013 Mar 15;34(7):583-92. &11. Xia G, You X, Liu L, Liu H, Wang J, Shi Y, Li P, Xiong B*, Liu X, Shen J* Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors. Eur J Med Chem. . &12. Linrong Zhu, Yuanyuan Li, Ling Qiu, Mingbo Su, Xin Wang, Chunmei Xia, Yi Qu,Jingya Li, Jia Li,* Bing Xiong,* and Jingkang Shen*Design and Synthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as Dipeptidyl Peptidase IV Inhibitors.ChemMedChem. 04 - 1116. &13. Anjiang Yang, Ruwei Jiang, Oleg Khorev, Ting Yu,Yongliang Zhang, Lanping Ma, Guohua Chen, Jingkang Shen, * and Tao Meng*. Palladium-Catalyzed Route to Three-Component One-Pot Sequential Synthesis of Functionalized Cyclazines: 2,2a1,4-Triazacyclopenta[cd]indenes. Adv. Synth. Catal. , 1984 - 1988. &14. Yiquan Zou, Lei Xu, Wuyan Chen, Yiping Zhu, Tiantian Chen , Yan Fu, Li Li , Lanping Ma, Bing Xiong, Xin Wang , Jian Li, Jianhua He , Haiyan Zhang , Yechun Xu *, Jia Li *, Jingkang Shen*. Discovery of pyrazole as C-terminus of selective BACE1 inhibitors. Eur J Med Chem. -283. &15. Yiquan Zou , Li Li, Wuyan Chen, Tiantian Chen , Lanping Ma, Xin Wang, Bing Xiong *, Yechun Xu,* and Jingkang Shen,*. Virtual Screening and Structure-Based Discovery of Indole Acylguanidines as Potent β-secretase (BACE1) Inhibitors. Molecules 06-5722. &16. Yu Z, Ma YC, Ai J, Chen DQ, Zhao DM, Wang X, Chen YL, Geng MY, Xiong B, Cheng MS, Shen JK. Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations. Acta Pharmacol Sin. ):1475-83. &17. Ren J, Li J, Shi F, Wang X, He JH, Xu YC, Zhang NX, Xiong B, Shen JK.[Progress in the fragment-based drug discovery]. Yao Xue Xue Bao. ):14-24. Review. Chinese. &18. Xia G, Liu L, Liu H, Yu J, Xu Z, Chen Q, Ma C, Li P, Xiong B, Liu X, Shen J. Design and synthesis of (R)-1-arylsulfonylpiperidine-2-carboxamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors. ChemMedChem. ):577-81 &19. Hui Xie,* Juan Liu,+ Min Yu,+ Yong Wang,* Chunyan Yao * Shuyi Yao,? Di Jin,+ Dingyu Hu,? Yanlin Wang,§Jingkang Shen? and Shengli Pan*. Structure-Activity Relationship of 39 Analogs of Laetispicine with Antidepressant Properties. AMERICAN JOURNAL OF CHINESE MEDICINE , . &20. Guanghua Fang , Mengzhu Xue, Mingbo Su, Dingyu Hua,Yanlian Li, Bing Xiong*, Lanping Ma, Tao Meng, Yuelei Chen, Jingya Li, Jia Li* , Jingkang Shen*. CCLab--a multi-objective genetic algorithm based combinatorial library design software and an application for histone deacetylase inhibitor design. Bioorg Med Chem Lett. 22 ,45. &21. Huayong Zhou, Wei Wang, Oleg Khorev, Yongliang Zhang, Zehong Miao Tao, Meng,* and Jingkang Shen*, Three-Component, One-Pot Sequential Synthesis of Tetracyclic Pyrido[2’,1’:2,3]imidazo[5,1-a]isoquinolinium Compounds as Potent Anticancer Agents. Eur. J. Org. Chem. -5594. &22. Lu Ma, Dongmei Zhao, Lin Chen, Xin Wang, Yue-Lei Chen*, Jingkang Shen*. (N,N-Diisopropylcarbamoyloxy)-methyl p-tolyl sulfone: preparation and application for the syntheses of 1,2-diols.Tetrahedron 68 ,e8711. &23. Danqi Chen, Ying Wang, Yuchi Ma, Bing Xiong, Jing Ai, Yi Chen, Meiyu Geng* and Jingkang Shen*.Discovery of 3H-Imidazo[4,5-b]pyridines as Potent c-Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation. ChemMedChem 57 - 1070. &24. Shuyi Yao , Hui Xie , Li Zhang , Tao Meng , Yongliang Zhang , Xin Wang , Lin Chen ,Shengli Pan , and Jingkang Shen*.Total Synthesis and Antidepressant Activities of Laetispicine and Its Derivatives. Molecules .25-1436; &25. Guangxin Xia, Lin Liu, Mengzhu Xue, Haiyan Liu, Jianxin Yu, Ping Li, Qian Chen, Bing Xiong*, Xuejun Liu, Jingkang Shen*.Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11b-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol. (1):46-52. &26. Jianxin Yu, Haiyan Liu, Guangxin Xia,*, Lin Liu, Zhenmin Xu, Qian Chen, Chen Ma, Xing Sun, Jiajun Xu, Hua Li, Ping Li, Yufang Shi, Bing Xiong, Xuejun Liu, and Jingkang Shen*. Discovery of 2-Alkyl-1-arylsulfonylprolinamides as 11β- Hydroxysteroid Dehydrogenase Type 1 Inhibitors. ACS Med. Chem. Lett. 3-798. &27. Sun. H.P, Zhou H. Y., Khorev O., Jiang R.W., Yu T., Wang X., Du Y.L, Ma Y., Meng T.*, Shen J.K.* Three-Component, One-Pot Sequential Synthesis of Functionalized Cyclazines: 3H-1,2a1,3-Triazaacenaphthylenes, J. Org. Chem. 745-10751 &28. Ying Ma, Fuzhen Yang, Ying Wang, Zhiyan Du, Daihua Liu, Hongxia Guo, Jingkang Shen, Hongli Peng*.CaMKKb Is Involved in AMP-Activated Protein Kinase Activation by Baicalin in LKB1 Deficient Cell Lines. PLOS ONE,2012,7, e47900. &29. Meng, T.; Zou, Y.; Khorev, O.; Jin, Y.; Zhou, H.; Zhang, Y.; Hu, D.; Ma, L.; Wang, X.; Shen, J. Simple and Efficient Copper(I)-Catalyzed Access to Three Versatile Aminocoumarin-Based Scaffolds using Isocyanoacetate. Adv Synth Catal 4 &30. Jin-Feng Liu, Ying Ma, Ying Wang, Zhi-Yan Du, Jing-Kang Shen and Hong-Li Peng*. Reduction of Lipid Accumulation in HepG2 Cells by Luteolin is associated with Activation of AMPK and Mitigation of Oxidative Stress. Phytother. Res. 8-596. &31. Feng Shi, Jing Kang Shen, Danqi Chen,Karina Fog, Kenneth Thirstrup, Morten Hentzer, Jens-Jakob Karlsson, Veena Menon, Kenneth A. Jones, Kelli E. Smith, and Garrick Smith. Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139 ACS Medicinal Chemistry Letters，),303-306. &32. Dan-qi CHEN, Xin WANG, Lin CHEN, Jin-xue HE, Ze-hong MIAO, Jing-kang SHEN* Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization .Acta Pharmacologica Sinica (4-67. &33. Xia G, Xue M, Liu L, Yu J, Liu H, Li P, Wang J, Li Y, Xiong B, Shen J. Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5739-44. &34. Fong DH, Xiong B, Hwang J, Berghuis AM. Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. PloS One. 2011 May 9;6(5):e19589. &35. 柴茜，沈强，马兰萍,，王昕，孟韬，李静雅，李佳，沈竞康 , 基于四氢喹啉酸骈环烯骨架的蛋白酪氨酸磷酸酯酶1B抑制剂的设计、合成及构效关系研究，高等学校化学学报，),306-315. &36. Shen Q, Xiong B, Zheng M, Luo X, Luo C, Liu X, Du Y, Li J, Zhu W, Shen J, Jiang H. Knowledge-based scoring functions in drug design: 2. Can the knowledge base be enriched? J Chem Inf Model. 2011 Feb 28;51(2):386-97 . &37. Meng, T.; Zhang, Y.; Li, M.; Wang, X.; Shen, J. Synthesis of Novel Substituted Benzimidazo[1,2- a]quinoxalin-6(5H)-ones via an Intramolecular Goldberg Reaction. J Comb Chem -224. &38. Meng, T.; Wang, J.; Peng, H.; Fang, G.; Li, M.; Xiong, B.; Xie, X.; Zhang, Y.; Wang, X.; Shen, J. Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J.Med.Chem 3-1139. &39. Bing Xiong*, Jie Wu, David L Burk, Mengzhu Xue, Hualiang Jiang, Jingkang Shen*. BSSF：a fingerprint based ultrafast binding site similarity search and function analysis server. BMC Bioinformatics,. &40. Zhang Liu, Qian Chai,, Yuan-yuan Li,, Qiang Shen, Lan-ping Ma, * Li-na Zhang, Xin Wang, Li Sheng, Jing-ya, Jing-kang SHEN. Discovery of novel PTP1B inhibitors with antihyperglycemic activity. Acta Pharmacologica Sinica.5-1012. &41. Yongli Du , Qunyi Li, Bing Xiong, Xin Hui, Xin Wang, Yang Feng, Tao Meng, Dingyu Hu,Datong Zhang, Mingwei Wang,*, Jingkang Shen,*Aromatic b-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists. Bioorg.Med,Chem. 55-4268. &42. Mengzhu Xue, Mingyue Zheng, Bing Xiong,* Yanlian Li, Hualiang Jiang, and Jingkang Shen*Bing Xiong* Knowledge-Based Scoring Functions in Drug Design. 1. Developing a Target-Specific Method for Kinase-Ligand Interactions.J. Chem. Inf. Model. 78-1386. &43. HongLi Peng & Gordon C. Yaney & Michael T. Kirber. Modulation of Ca2+ release through ryanodine receptors in vascular smooth muscle by protein kinase Cα. Pflugers Arch - Eur J Physiol, 1-802. &44. Ling Qing, Zhou Yue-yang, Cai Zheng-liang, Zhang Ya-hui, Xiong Bing, Ma Lan-ping,Wang Xin, Li Xin, Li Jia, Shen Jing-kang. Synthesis and LAR inhibition of 7-alkoxy analogues of illudalic acid. Acta Pharmaceutica Sinica )，. &45. Hong-xia GUO, Dai-hua LIU， Ying MA, Jin-feng LIU, Ying WANG, Zhi-yan DU, Xin WANG, Jing-kang SHEN, Hong-li PENG*，Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet, Acta Pharmacol Sin, 2009 ; 30, ; &46. Bi-bo YAN, Meng-zhu XUE, Bing XIONG*, Ke LIU, Ding-yu HU, Jing-kang SHEN*, ScafBank: A Public Comprehensive Scaffold Database to Support Molecular Hopping, Acta Pharmacol Sin, 2009 ; 30（2）,251-258; &47. Yiping Zhu, Kun Xiao, Lanping Ma, Bin Xiong, Yan Fu, Haiping Yu, Wei Wang, Xin Wang, Dingyu Hu, Hongli Peng, Jingya Li, Qi Gong, Qian Chai, a Xican Tang, Haiyan Zhang*, Jia Li*, and Jingkang Shen*, Design, Synthesis and Biological Evaluation of Novel Dual Inhibitors of Acetylcholinesterase and β-Secretase, Bioorg. Med. Chem. 00-1613; &48. Yi-ping ZHU, Kun XIAO, Hai-ping YU, Lan-ping MA, Bing XIONG, Haiyan ZHANG, Xin WANG, Jing-ya LI, Jia LI*, Jing-kang SHEN*, Discovery of potent β-secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids, Acta Pharmacol Sin, 2009 ; 30 (2) , 250-270.&网页优化工具
使用说明：
①、本网站速度诊断平台目前包括几大部分：网页抓图、时间线、对象分析、网页统计以及优化建议。
②、网站速度诊断对网站所有元素进行扫描分析，以为参照标准，给出相应的性能优化建议。
③、本诊断的目的是为您找出影响网页速度的因素，从而加以优化改善。
④、建议尽量优化您的网页，把您的网页打开时间控制在6秒以内。
⑤、诊断过程如有任何问题，请加入本站QQ交流群（），。
耗时(s)最近测试：
网站速度诊断
高级诊断(PC)
高级诊断(移动)
-669.0kB0.0s
下载用时:&31ms
响应HeaderServer:
squid/3.5.20Date:
Fri, 11 Nov :46 GMTContent-Type:
text/ charset=GB2312Transfer-Encoding:
chunkedConnection:
keep-aliveVary:
Accept-Encoding,Accept-Encoding,Accept-EncodingExpires:
Fri, 11 Nov :46 GMTCache-Control:
max-age=60Content-Encoding:
gzipX-Cache:
总计685.1100各域名请求耗时域名s%0.03100.0总计0.03100各域名请求数量域名%1100.0总计1100各类型体积统计类型kB%Javascript0.00.0CSS0.00.0Image0.00.0其他685.1100.0总计685.1100各类型耗时统计类型s%Javascript0.000.0CSS0.000.0Image0.000.0其他0.03100.0总计0.03100请求有效性统计类别%有效请求1100.0无效请求00.0总计1100
查看所有节点状态
（注：“公开”表示测试结果出现在最近测试列表里，公共可见）
保存记录：
（注：保存记录后可在“测试历史”里查看历史记录，仅当前电脑可见）
功能说明：
为满足不同用户的需求，用户可以选择不同的线路和浏览器进行测试。
注意事项：
--如果线路浏览器不满足您的选项要求，系统将随机分配。
User-Agent：
视图分析：
功能说明：
1、可以设置打开网页的客户端带宽。
2、如果选择Chrome浏览器测试，可以设置User Agent。
3、可以选择是否需要进行视图分析。
注意事项：
--使用视图分析的网页请求数不能超过150个
--只分析前30秒或前50张网页截图
--只生成前15秒网页录像
那么，这里应该输入：
密码HTML ID：
(这个是密码输入框的HTML id名称)&&实例说明
那么，这里应该输入：
登录HTML ID：
(这个是登录按钮的HTML id名称)&&实例说明
那么，这里应该输入：
用户帐号：
(这个是网页登录的用户帐号名称)
帐号密码：
(这个是网页登录的用户帐号密码)
功能说明：
网页打开后可以进行登录访问。
注意事项：
--网页登录不要新开窗口
--为了帐号安全，请务必使用测试帐号，并且测试完毕及时更改密码
那么，这里应该输入：
查看详细信息
点击按钮或图标：
(这里输入按钮或图标的HTML id名称)&&实例说明
那么，这里应该输入：
功能说明：
网页打开后还可以点击某个链接或按钮图标进行深度访问。
注意事项：
--网页打开需在当前窗口，不能新开窗口
--不能同时设置“网页登录”和“二次点击”，同时设置后只进行“网页登录”
正在进行初始化...
您的选项：线路（），浏览器（）
【注：如果线路浏览器不满足您的选项要求，系统将随机分配】
很抱歉！诊断出现异常，请检查您的输入是否正确。
没有符合条件的可用节点，所有节点状态。
网站得分 加载中...
网站性能优化您懂多少？
超过40个来自Google PageSpeed和Yahoo YSlow的网站性能优化建议，从简单到复杂，从入门到高深，大部分优化都配有实例演示，是您优化网站性能的绝佳参考资料。
说明：- 历史记录显示的只是当前浏览器的测试历史，且只能本机可见。- 如果浏览器禁用Cookie，将不能保存测试记录，但你仍可以通过永久链接访问。
正在生成报告，请稍候...
生成报告失败，请稍后再试。如有问题，请。
移动设备：
iPhone6Plus
（注：“公开”表示测试结果出现在最近测试列表里，公共可见）
保存记录：
（注：保存记录后可在“测试历史”里查看历史记录，仅当前电脑可见）
功能说明：
为满足不同用户的需求，用户可以选择不同的线路和浏览器进行测试。
注意事项：
--如果线路浏览器不满足您的选项要求，系统将随机分配。
功能说明：
1、可以设置打开网页的客户端带宽。
那么，这里应该输入：
密码HTML ID：
(这个是密码输入框的HTML id名称)&&实例说明
那么，这里应该输入：
登录HTML ID：
(这个是登录按钮的HTML id名称)&&实例说明
那么，这里应该输入：
用户帐号：
(这个是网页登录的用户帐号名称)
帐号密码：
(这个是网页登录的用户帐号密码)
功能说明：
网页打开后可以进行登录访问。
注意事项：
--网页登录不要新开窗口
--为了帐号安全，请务必使用测试帐号，并且测试完毕及时更改密码
那么，这里应该输入：
查看详细信息
点击按钮或图标：
(这里输入按钮或图标的HTML id名称)&&实例说明
那么，这里应该输入：
功能说明：
网页打开后还可以点击某个链接或按钮图标进行深度访问。
注意事项：
--网页打开需在当前窗口，不能新开窗口
--不能同时设置“网页登录”和“二次点击”，同时设置后只进行“网页登录”
正在进行初始化...
您的选项：线路（），移动设备（）
【注：如果线路或移动设备不满足您的选项要求，系统将随机分配】
很抱歉！诊断出现异常，请检查您的输入是否正确。
没有符合条件的可用节点，所有节点状态。
网站得分 加载中...
说明：- 历史记录显示的只是当前浏览器的测试历史，且只能本机可见。- 如果浏览器禁用Cookie，将不能保存测试记录，但你仍可以通过永久链接访问。
正在生成报告，请稍候...
生成报告失败，请稍后再试。如有问题，请。
QQ交流群（）